Thyrocare Technologies Limited has been informed by its promoter, Docon Technologies Private Limited, about the release of a pledge on 1,75,00,000 equity shares. The pledge, held by Catalyst Trusteeship Limited as Debenture Trustee, was released on August 11, 2026. This event clarifies Docon’s shareholding structure, reducing the number of encumbered shares and reinforcing its direct control over its stake in Thyrocare.
Promoter Share Pledge Released
Thyrocare Technologies Limited announced that its promoter, Docon Technologies Private Limited, has successfully released a significant portion of its pledged shares. Specifically, 1,75,00,000 equity shares of Thyrocare Technologies Limited, previously encumbered, are no longer pledged.
Details of the Release
The release was executed by Catalyst Trusteeship Limited, acting in its capacity as the Debenture Trustee. The transaction took place on August 11, 2026. This release reduces the encumbered shareholding of Docon Technologies, impacting its overall pledge status and further solidifying its direct holdings.
Shareholding Context
Prior to this release, Docon Technologies held 9,69,69,696 equity shares, representing 60.92% of Thyrocare’s equity. These shares were pledged as security for Non-Convertible Debentures (NCDs) issued by API Holdings Limited, Docon’s holding company. Following the release of 1,75,00,000 shares, Docon’s encumbered shareholding now stands at 7,94,69,696 equity shares, while its total shareholding remains unchanged.
The total outstanding principal amount of the NCDs is INR 10,500 million. The company has provided detailed disclosures as per the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding this release of pledge.
Source: BSE
